Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01136733 · ClinicalTrials.gov registry record · Phase 1
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
A Phase 1 study of Metastatic Renal Cell Carcinoma, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 173
- Enrollment target
- 20
- Study locations
NCT01136733 is a Phase 1 study of Metastatic Renal Cell Carcinoma that has completed, run by Eisai. The registered enrollment target is 173 participants, above the 139-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01136733, a Phase 1 study of Metastatic Renal Cell Carcinoma, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 173 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, Phase 1b/2 study of lenvatinib alone and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Lenvatinib
Study Locations (20)
Other
- - Brno
- - Olomouc
- - Prague
- - Gdansk
- - Lodz
- - Szczecin
California
- - Orange
- - San Diego
Maryland
- - Annapolis
- - Bethesda
Arizona
- - Tucson
Florida
- - Tampa
Illinois
- - Joliet
Kentucky
- - Louisville
Massachusetts
- - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2010-08-05 |
| Est. Completion | 2018-02-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01136733
The ClinicalTrials.gov registry entry for NCT01136733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 139-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (24% higher). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.
NCT01136733 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT01136733 about?
NCT01136733 is a clinical study titled "A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment". This is an open-label, multicenter, Phase 1b/2 study of lenvatinib alone and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.
What is the current status of trial NCT01136733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 173 participants. The study started on 2010-08-05. Estimated completion is 2018-02-08.
What conditions does trial NCT01136733 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT01136733?
The interventions under investigation include: Everolimus (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT01136733?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01136733 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
RECRUITING · Phase 1
-
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 1
-
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.